Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Sodium Sulfate

Phase 2Small molecule

SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Sodium Sulfate is one of 38 small molecule programs targeting Toxicity. It is currently in Phase 2.

1

Indications

2

Total Trials

1

Active Trials

37

Competitors

Pipeline

Status by Indication[3][1]

Indication

ToxicityActive, not recruiting

ToxicityPhase 2

Active, not recruiting

Competition

Competitive Landscape

223 competitors in Toxicity

#DrugCompanyPhaseTrials

Cytotec

Erbitux

Mucosta

Sustiva

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Paracetamol

Cysteine Hydrochloride

Tenofovir/emtricitabine/rilpivirine

MMahidol University

Afinitor

Imfinzi

Cellcept

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Infection1 trial

Clinical Investigation of Chemomechanical Parameters for an Efficient Disinfection of the Root Canal

Active, not recruiting·NNational and Kapodistrian University of Athens·N/A·NCT06949176·44 enrolled

Toxicity1 trial

Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05877911·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Sodium Sulfate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sodium Sulfate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sodium Sulfate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Related News